ArticleFrontiers in oncology2021
A Pilot Study of
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Transrectal Ultrasound-Guided Prostate Biopsy with and without PSMA-PET-Targeted Prostate Biopsy for Prostate Cancer Diagnosis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Article
- Exploration of a novel quantitative model based on PRIMARY score in the diagnosis of clinically significant prostate cancer using [18F]PSMA PET/CT.World journal of urology · 2025Article
- The evolving role of positron emission tomography in precision prostate cancer biopsy.European journal of clinical investigation · 2025Review
- Comparison betweenAsian journal of urology · 2025Article
- Advances in imaging and artificial intelligence for precision diagnosis and biopsy guidance in prostate cancer.Frontiers in oncology · 2025Review
- A Pilot Study of PSMA PET/CT and MRI Fusion for Prostate Cancer: Software to Replace PET/MRI Hardware.Journal of clinical medicine · 2024Article
- The first-in-human preclinical evaluation of the new probe [123I]I-PSMA-7 for real-time intraoperative targeted biopsy and SPECT/CT imaging in prostate cancer.European journal of nuclear medicine and molecular imaging · 2024Article
- Prostate-specific membrane antigen-targeted surgery in prostate cancer: Accurate identification, real-time diagnosis, and precise resection.Theranostics · 2024Review
- Histopathology-validated lesion detection rates of clinically significant prostate cancer with mpMRI, [ 68 Ga]PSMA-11-PET and [ 11 C]Acetate-PET.Nuclear medicine communications · 2023Article
- CanTranslational andrology and urology · 2023Article
- A Preclinical Study of anPharmaceuticals (Basel, Switzerland) · 2022Article
- The use of advanced imaging in guiding the further investigation and treatment of primary prostate cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022Review
- Could 68Ga-PSMA PET/CT Evaluation Reduce the Number of Scheduled Prostate Biopsies in Men Enrolled in Active Surveillance Protocols?Journal of clinical medicine · 2022Article
- A clinical trial of super-stable homogeneous lipiodol-nanoICG formulation-guided precise fluorescent laparoscopic hepatocellular carcinoma resection.Journal of nanobiotechnology · 2022Article
- Article
- Role of molecular imaging in the detection of localized prostate cancer.Therapeutic advances in urologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe purpose of this study was to evaluate the feasibility and diagnostic performance of prostate-specific membrane antigen (PSMA) based
methodsFrom April 2018 to November 2019, we prospectively enrolled 55 candidates to perform PET/CT-US or PET/MRI-US fusion targeted biopsies for solitary PET-positive prostate lesions (two to four cores/lesion). The positive rates of prostate cancer based on patients and biopsy cores were calculated respectively. With reference to the pathological results of biopsy cores, the MR signal characteristics in the area of the PET-positive lesion were analyzed for the patients who underwent PET/MRI.
resultsA total of 178 biopsy cores were taken on the 55 patients. One hundred forty-six biopsy cores (82.0%, 146/178) from 51 (92.7%, 51/55) patients were positive for prostate cancer; 47 (85.5%, 47/55) were clinically significant prostate cancer. It is noteworthy that nine patients underwent both
conclusionThis study indicated that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.